Results of sofosbuvir‐based combination therapy for chronic hepatitis C cohort of Indian patients in real‐life clinical practice. Issue 4 (April 2017)

• Record Type: Journal Article
• Authors: Sood, Ajit; Midha, Vandana; Mahajan, Ramit; Narang, Vikram; Mehta, Varun; Wander, Praneet; Sharma, Suresh; Kaur, Kirandeep; Singh, Dharmatma
• Is Part Of: Journal of gastroenterology and hepatology. Volume 32:Issue 4(2017)
• Page Start: 894
• Page End: 900
• Publication Date: 2017-04
• Subjects: chronic hepatitis C -- real‐life experience -- sofosbuvir -- SVR; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.13628
• Languages: English
• ISSNs: 0815-9319

Abstract

Abstract: Background and Aim: The introduction of sofosbuvir has revolutionized the treatment of chronic hepatitis C. This study was planned to observe whether the efficacy and tolerability of sofosbuvir‐based regimens demonstrated in phase 3 clinical trial results translate into real‐life clinical practice. Methods: This prospective, non‐randomized observational study conducted in Dayanand Medical College and Hospital, Punjab, included all consecutive treatment‐naïve patients with chronic hepatitis C (genotypes 1–5) who were treated with sofosbuvir‐based regimens. Response to therapy was assessed at week 4 (rapid virological response), week 12 or 24 (end of treatment response), and 12 weeks after cessation of therapy (sustained virological response [SVR]). Results: Of 947 patients diagnosed with chronic hepatitis C virus and considered for treatment with direct‐acting antivirals, 736 patients (77.1%) opted for treatment (age 45.1 ± 10.1 years, 64% men, genotype 3 [80%], genotype 1 [14.7%], and genotype 4 [4.9%]). Viral load was high (>600 000 IU/mL) in 361/736 (49%); 330 patients (44.8%) had cirrhosis (80 [14.3%] were decompensated). Patients with genotypes 1, 4, and 5 ( n = 135) were treated with triple drug regime (pegylated interferon, ribavirin, and sofosbuvir) for 12 weeks. Patients with genotype 3 ( n = 589) were treated either with dual therapy (sofosbuvir and ribavirin) for 24 weeks ( n = 405) or triple therapy for 12 weeks ( n = 184). SVR was achieved in 453/473 (95.8%). SVR rates did not differ among different genotypes but were higher in non‐cirrhotics. Conclusion: Sofosbuvir‐based treatment regimens achieve high SVR rates in real‐life cohort of Indian patients with chronic hepatitis C infection (including those with cirrhosis).